1 results match your criteria: "1. Excel Diagnostics and Nuclear Oncology Center[Affiliation]"
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.
Theranostics
October 2012
1. Excel Diagnostics and Nuclear Oncology Center, 9701 Richmond Avenue, suite 122, Houston, Texas, 77042;
Aim: To study the long term benefits, toxicity and survival rate in patients with neuroendocrine tumors receiving multiple cycles of high activity In-111 Pentetreotide therapy. Moreover, our secondary aim was to evaluate the value of F-18 FDG PET-CT scan as prognostic indicator in this group of patients.
Background: Neuroendocrine tumors are a heterogeneous group of malignancies which are usually metastatic at diagnosis.